RCUS · Arcus Biosciences, Inc.
$24.44
-0.79 (-3.13%)
At close · Oct 2
Return incl. dividend (before tax)
Market Cap
$3.18B
Shares
127.33M
Volume · Oct 2
1.04M
Avg daily vol (3M)
1.31M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$24.44
Open$25.48
Day$24.09–25.58
52W close$13.35–31.57
Avg vol 30d1.5M
Short int13.8M · 10.8% float · 7.8d
Short vol42%
Last earningsAug 5, 2026
DataJan 2020–Oct 2026
Filing10-Q · Aug 5
Up next
Next earnings call
Nov 5, 2026
Est · unconfirmed
· in 5 wks
filed Aug 5, 2026
call held Aug 5, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$117.00M
Trailing 12 months
Net income (TTM)
−$460.00M
Trailing 12 months
Revenue growth YoY
-74.4%
Year over year
Operating margin
-415.4%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-14.9%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$49.00M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+18.4%
Year over year · more shares
Price change (1Y)
+87.2%
Trailing year
Short interest
10.8%
Latest settlement · 7.8 days to cover
AI Brief
Q2 FY26 earnings call · Aug 5, 2026
Q2 FY26
TL;DR. Arcus reported Q2 results, executed three new clinical trial collaborations with BMS, Summit, and AVEO to expand casdatifan combinations across lines of ccRCC therapy, and remains on track to complete PEAK-1 enrollment and initiate the PEAK-20 registrational trial by year-end 2026, with $775M in cash providing runway into at least 2H 2028.
Bullish
- + Three new clinical collaborations expand casdatifan combinations across front-line and late-line ccRCC
- + PEAK-1 enrollment on track to complete by year-end 2026
- + First front-line registrational PEAK-20 trial expected to initiate by year-end 2026
- + Multiple ARC-20 casdatifan data readouts expected in 2H 2026 across first-line, second-line, and late-line settings
- + Casdatifan Nature publication demonstrates deep and sustained HIF-2α suppression correlating with higher response rates and longer PFS
- + $775M cash provides runway into at least 2H 2028
Bearish
- − Q2 revenue declined sharply year-over-year to $41M from $160M
- − Q2 net loss of $91M compared to break-even in prior year quarter
- − Wind-down of domvanalimab program and Phase 3 PACIFIC-8 discontinuation ending collaboration
- − Full-year 2026 GAAP revenue guided to $65-75M reflecting lower collaboration revenue
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Neutral
Momentum
Neutral
Sentiment
Neutral
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 15.3 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−1%
below
Price vs 50-day avg
−12%
below
RSI (14)
37
neutral
MACD trend
Positive
52-week position
61%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−19%
trailing
6-month return
+9%
trailing
YTD return
+3%
this year
Relative strength
−3%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $28 › 200d $25 — 50d above 200d
Institutional flow
Flat
1 of 233 funds reported for Sep 30 · net 0 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
10.85% of float · ▲ +5.6% MoM · 7.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
233 holders — near 3-yr high, broad support
Squeeze score
60
elevated · 0–100
Fundamentals
Revenue growth
−4%
Y/Y
EPS growth
−5%
Y/Y
Free cash flow
$-484.0M
Balance sheet
$123.0M
net cash
Quant / Vol
risk profile
Volatility
62%
annualized · 1-yr
Max drawdown
−28%
past year
ATR
5.3%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Aug 5, 2026
end of 2026
Cash, cash equivalents and marketable securities (year-end balan
$600M
full year 2026
GAAP revenue
GAAP
Initiated
$65M – $75M
prior FY $247M
midpoint −71.7% Y/Y
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−1%
Neutral
Price vs 50-day avg
−12%
Bearish
RSI (14)
37
Neutral
MACD trend
Positive
Bullish
52-week position
61%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $28 › 200d $25 — 50d above 200d
Institutional flow
Flat
1 of 233 funds reported for Sep 30 · net 0 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
10.85% of float · ▲ +5.6% MoM · 7.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
233 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $13
Now $24 · 61%
Range high $32
vs 200-day avg -1%
vs 50-day avg -12%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
RCUS
this stock
Arcus Biosciences, Inc.
|
$3.18B | +2.6% | -4.3% | — | 10.8% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +11.3% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -4.8% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +544.3% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| RCUS | -2.1% | -18.9% | +9.2% | -5.4% | +2.6% |
| SPY | -0.2% | -0.5% | +12.2% | +0.9% | +12.9% |
| vs SPY | -1.9% | -18.4% | -3.0% | -6.3% | -10.3% |